Alere Home Monitoring 8-A12B Registration of securities on exchange

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934

FREE & CLEAR, INC.

(Exact name of registrant as specified in its charter)

Delaware	20-0231080
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)
51 Sawyer Road, Suite 200 Waltham, MA	02453
(Address of principal executive offices)	(Zip Code)

TAPESTRY MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	20-0391730
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)
51 Sawyer Road, Suite 200 Waltham, MA	02453
(Address of principal executive offices)	(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered	Name of each exchange on which each class is to be registered
Guarantee of 9.00% Senior Subordinated Notes due 2016 of Inverness Medical Innovations, Inc.	New York Stock Exchange

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.   þ

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.   o

Securities Act registration statement file number to which this form relates:                    

Securities to be registered pursuant to Section 12(g) of the Act: None

TABLE OF CONTENTS

	Item 1. Description of Registrant’s Securities to be Registered
	Item 2. Exhibits
SIGNATURE
Ex-4.7 Fifth Supplemental Indenture dated as of November 25, 2009

Explanatory Note

     On May 12, 2009, Inverness Medical Innovations, Inc., a Delaware corporation (“Inverness”), issued its 9.00% senior subordinated notes due 2016 (the “Notes”), which were guaranteed (the “Guarantees”) by certain of its wholly owned subsidiaries (the “Original Guarantors”) pursuant to an indenture dated May 12, 2009 between Inverness and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture dated May 12, 2009 among Inverness, the Trustee and the Original Guarantors, as further supplemented by a second supplemental indenture dated June 9, 2009 among Inverness, the Trustee, the Original Guarantors and Matria of New York, Inc., a wholly owned subsidiary of Inverness (“Matria”), as guarantor, as further supplemented by a third supplemental indenture dated August 4, 2009 among Inverness, the Trustee, the Original Guarantors, Matria, GeneCare Medical Genetics Center, Inc., a wholly owned subsidiary of Inverness (“GeneCare”) and Alere CDM LLC, a wholly owned subsidiary of Inverness (“Alere”), collectively as guarantors, and as further supplemented by a fourth supplemental indenture dated September 22, 2009 among Inverness, the Trustee, the Original Guarantors, Matria, GeneCare, Alere, and ZyCare, Inc., a wholly owned subsidiary of Inverness (“ZyCare”), as guarantor (together, the “Indenture”). The Notes, the Guarantees, the Guarantee of Matria (the “Matria Guarantee”), the Guarantee of GeneCare (the “GeneCare Guarantee”), the Guarantee of Alere (the “Alere Guarantee”), and the Guarantee of ZyCare (the “ZyCare Guarantee”) are listed on the New York Stock Exchange and were registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), pursuant to a registration statement on Form 8-A filed on May 12, 2009, with respect to the Notes and the Guarantees, a registration statement on Form 8-A filed on June 9, 2009, with respect to the Matria Guarantee, a registration statement on Form 8-A filed on August 4, 2009, with respect to the GeneCare Guarantee and the Alere Guarantee, and a registration statement on Form 8-A filed on September 24, 2009 with respect to the ZyCare Guarantee. The terms of the Indenture provide that certain subsidiaries of Inverness must become guarantors of the Notes. On November 25, 2009, Inverness, the Trustee, the Original Guarantors, Matria, GeneCare, ZyCare, and the registrants, each a wholly owned subsidiary of Inverness, entered into a fifth supplemental indenture whereby the registrants agreed to guarantee the obligations of Inverness under the Notes on the same basis as the other Original Guarantors, Matria, GeneCare, Alere, and ZyCare. This registration statement on Form 8-A is being filed by the registrants in order to register its Guarantee under Section 12(b) of the Exchange Act to the same extent as the Original Guarantors, Matria, GeneCare, Alere, and ZyCare.

Item 1. Description of Registrant’s Securities to be Registered.

     The description of the registrants’ Guarantees is set forth under (a) the section captioned “Description of Debt Securities and Subsidiary Guarantees We May Offer” in the prospectus dated May 1, 2009 filed by Inverness and the Original Guarantors on May 4, 2009 pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which is a part of the registration statement on Form S-3 (No. 333-158542) filed by Inverness, the Original Guarantors and Matria, as supplemented by (b) the section captioned “Description of Notes” in the prospectus supplement dated May 7, 2009 filed by Inverness and the Guarantors on May 8, 2009 pursuant to

2

Rule 424(b) under the Securities Act of 1933, as amended, which descriptions are incorporated by reference into this registration statement and deemed to be a part hereof.

Item 2. Exhibits.

4.1	Indenture dated May 12, 2009 among Inverness Medical Innovations, Inc., as issuer, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to Inverness’ Current Report on Form 8-K dated May 12, 2009)
4.2	Supplemental Indenture dated May 12, 2009 among Inverness Medical Innovations, Inc., as issuer, the co-registrant guarantor subsidiaries, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.2 to Inverness’ Current Report on Form 8-K dated May 12, 2009)
4.3	Form of 9.00% Senior Subordinated Note due 2016 of Inverness Medical Innovations, Inc. (included in Exhibit 4.2 above)
4.4	Second Supplemental Indenture dated as of June 9, 2009 among Inverness Medical Innovations, Inc., as issuer, Matria of New York, Inc., as guarantor, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.4 to Matria of New York’s Registration Statement on Form 8-A dated June 9, 2009)
4.5	Third Supplemental Indenture dated as of August 4, 2009 among Inverness Medical Innovations, Inc., as issuer, GeneCare Medical Genetics Center, Inc. and Alere CDM LLC, collectively as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.5 to GeneCare Medical Genetics Center, Inc. and Alere CDM LLC’s Registration Statement on Form 8-A dated August 4, 2009)
4.6	Fourth Supplemental Indenture dated as of September 22, 2009 among Inverness Medical Innovations, Inc., as issuer, ZyCare, Inc., as guarantor, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.6 to ZyCare, Inc.’s Registration Statement on Form 8-A dated September 24, 2009)
4.7	Fifth Supplemental Indenture dated as of November 25, 2009 among Inverness Medical Innovations, Inc., as issuer, Free & Clear, Inc. and Tapestry Medical, Inc., collectively as guarantors, and U.S. Bank National Association, as trustee

3

SIGNATURE

     Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

FREE & CLEAR, INC. (Registrant)
By:	/s/ David A. Teitel
	Name:	David A. Teitel
	Title:	Vice President, Finance and Treasurer
TAPESTRY MEDICAL, INC. (Registrant)
By:	/s/ David A. Teitel
	Name:	David A. Teitel
	Title:	Vice President, Finance

Date: November 25, 2009

4